Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia

  • Technology appraisal guidance
  • TA29
  • Published: 
Download guidance (PDF)

9 Sources of Evidence

The following documentation and opinion was made available to the committee:

a. Assessment Report prepared by the Department of Public Health and Epidemiology, University of Birmingham (Fludarabine as second line therapy for B-Cell chronic lymphocytic leukaemia, January 2001)

Assessment Report Annexe prepared by the Department of Public Health and Epidemiology, University of Birmingham (Fludarabine as second line therapy for B-Cell chronic lymphocytic leukaemia: Effectiveness Annexe, May 2001)

Assessment Report Cost- Effectiveness Annexe prepared by Dr A J Fischer, NICE Appraisals Team, May 2001

b. Manufacturer/Sponsor submissions:

  • Schering Health Care Ltd

c. Professional/Specialist Group, Patient/Carer Group and Trade Association submissions:

  • British National Lymphoma Investigation and UK CCCR

  • British Committee for Standards in Haematology (BCSH)

  • CancerBACUP

  • Lymphoma Association

  • Macmillan Cancer Relief

  • Royal College of Pathologists

d. External expert and patient advocate submissions:

  • Dr Andrew MacMillan, Oncologist, Mount Vernon Hospital

  • Dr Peter Hoskin, Consultant Clinical Oncologist, Mount Vernon Hospital

  • Dr Tracey Murray, Lecturer/Practitioner, St George's Healthcare NHS Trust

  • Catriona Moore, Policy Officer, CancerBACUP

  • Judith Brodie, Head of Cancer Support Services, CancerBACUP

  • Catriona Gilmour Hamilton, Assistant Head of Information Services, The Lymphoma Association